In Vivo Combined Photoacoustic Imaging and Photothermal Treatment of HPV-Negative Head and Neck Carcinoma with NIR-Responsive Non-Persistent Plasmon Nano-Architectures
Valentina Frusca, Chiara Cavallini, Agata Zamborlin, Giuliana Drava, Virginia Barone, Lisa Gherardini, Mario Chiariello, Paolo Armanetti, Maria Laura Ermini, Luca Menichetti, Valerio Voliani
{"title":"In Vivo Combined Photoacoustic Imaging and Photothermal Treatment of HPV-Negative Head and Neck Carcinoma with NIR-Responsive Non-Persistent Plasmon Nano-Architectures","authors":"Valentina Frusca, Chiara Cavallini, Agata Zamborlin, Giuliana Drava, Virginia Barone, Lisa Gherardini, Mario Chiariello, Paolo Armanetti, Maria Laura Ermini, Luca Menichetti, Valerio Voliani","doi":"10.1002/adtp.202400110","DOIUrl":null,"url":null,"abstract":"<p>The combination of photoacoustic imaging (PAI) and photothermal therapy (PTT) is an attractive approach in cancer management due to the non-invasive features combined with real-time imaging and selective tissue damage by non-ionizing radiation. This approach is especially appealing for Head and Neck Squamous Cell Carcinoma (HNSCC) management, where up to 40% of patients require modifications of the treatment regimen. On the other hand, most of the agents developed for PAI/PTT suffer from persistence or re-shaping issues. Here, a unique non-persistent plasmon nano-architecture (<i>t</i>NAs-IRDye) is presented that simultaneously acts as a contrast agent for PAI and as a photothermal transducer for PTT. The <i>t</i>NAs-IRDye are fully characterized and evaluated in vitro and ex vivo, and their performance as theranostic agents is assessed in HPV-negative HNSCC murine models. A significant modulation of tumor growth is obtained in vivo upon intratumoral injection of <i>t</i>NAs-IRDye and subsequent NIR irradiation compared to the solely irradiated control. The outcomes of this study exhibit a noteworthy potential to foster the development of innovative clinical strategies for the management of HPV-negative head and neck carcinoma.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 10","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/adtp.202400110","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
The combination of photoacoustic imaging (PAI) and photothermal therapy (PTT) is an attractive approach in cancer management due to the non-invasive features combined with real-time imaging and selective tissue damage by non-ionizing radiation. This approach is especially appealing for Head and Neck Squamous Cell Carcinoma (HNSCC) management, where up to 40% of patients require modifications of the treatment regimen. On the other hand, most of the agents developed for PAI/PTT suffer from persistence or re-shaping issues. Here, a unique non-persistent plasmon nano-architecture (tNAs-IRDye) is presented that simultaneously acts as a contrast agent for PAI and as a photothermal transducer for PTT. The tNAs-IRDye are fully characterized and evaluated in vitro and ex vivo, and their performance as theranostic agents is assessed in HPV-negative HNSCC murine models. A significant modulation of tumor growth is obtained in vivo upon intratumoral injection of tNAs-IRDye and subsequent NIR irradiation compared to the solely irradiated control. The outcomes of this study exhibit a noteworthy potential to foster the development of innovative clinical strategies for the management of HPV-negative head and neck carcinoma.